Centessa Pharmaceuticals (CNTA) Insider Trading & Ownership $16.42 -0.53 (-3.13%) (As of 12:43 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage11.59%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$11.62 M Get CNTA Insider Trade Alerts Want to know when executives and insiders are buying or selling Centessa Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CNTA Insider Buying and Selling by Quarter Ad Porter & CompanyKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware of… yet have the potential to deliver colossal returns over the next four years. I’m not talking about Tesla, Palantir, or anything else you’ve heard parroted by the mainstream financial press. No. These are Trump’s Secret Stocks. It’s all waiting for you here. Centessa Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails12/26/2024Gregory M WeinhoffInsiderSell10,000$17.04$170,400.00 12/20/2024Saurabh SahaCEOSell55,000$17.44$959,200.00 12/17/2024Karen M AndersonInsiderSell10,624$17.32$184,007.68 12/17/2024Tia L BushCTOSell17,813$18.00$320,634.00 12/16/2024Iqbal J HussainGeneral CounselSell77,705$16.39$1,273,584.95 12/13/2024Karen M AndersonInsiderSell5,876$17.01$99,950.76 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 12/6/2024Saurabh SahaCEOSell87,496$18.46$1,615,176.16 11/25/2024Gregory M WeinhoffInsiderSell10,000$17.66$176,600.00 11/25/2024Saurabh SahaCEOSell299$18.23$5,450.77 11/22/2024Saurabh SahaCEOSell1,671$18.24$30,479.04 11/20/2024Saurabh SahaCEOSell55,000$16.89$928,950.00 10/25/2024Gregory M WeinhoffInsiderSell11,742$15.38$180,591.96 10/23/2024Saurabh SahaCEOSell2,592$15.32$39,709.44 10/21/2024Saurabh SahaCEOSell22,205$15.80$350,839.00 9/25/2024Gregory M WeinhoffInsiderSell16,619$15.69$260,752.11 9/20/2024Saurabh SahaCEOSell55,000$16.53$909,150.00 9/10/2024Saurabh SahaCEOSell175,000$16.52$2,891,000.00 9/9/2024Gregory M WeinhoffInsiderSell25,000$15.00$375,000.00 8/22/2024Gregory M WeinhoffInsiderSell12,198$12.17$148,449.66 8/22/2024Saurabh SahaCEOSell506$12.23$6,188.38 8/20/2024Saurabh SahaCEOSell4,169$12.32$51,362.08 3/25/2024Karen M AndersonInsiderSell51,160$11.88$607,780.80 2/1/2024Harris RotmanSVPSell4,267$8.10$34,562.70 (Data available from 1/1/2013 forward) CNTA Insider Trading Activity - Frequently Asked Questions Who is on Centessa Pharmaceuticals's Insider Roster? The list of insiders at Centessa Pharmaceuticals includes Antoine Yver, David J Grainger, David M Chao, Gregory M Weinhoff, Harris Rotman, Iqbal J Hussain, Karen M Anderson, Saurabh Saha, Thomas Templeman, and Tia L Bush. Learn more on insiders at CNTA. What percentage of Centessa Pharmaceuticals stock is owned by insiders? 11.59% of Centessa Pharmaceuticals stock is owned by insiders. Learn more on CNTA's insider holdings. Which Centessa Pharmaceuticals insiders have been selling company stock? The following insiders have sold CNTA shares in the last 24 months: Antoine Yver ($81,145.60), Gregory M Weinhoff ($1,311,793.73), Harris Rotman ($270,337.06), Iqbal J Hussain ($1,273,584.95), Karen M Anderson ($891,739.24), Saurabh Saha ($7,787,504.87), and Tia L Bush ($356,474.00). How much insider selling is happening at Centessa Pharmaceuticals? Insiders have sold a total of 777,696 Centessa Pharmaceuticals shares in the last 24 months for a total of $11,972,579.45 sold. Centessa Pharmaceuticals Key ExecutivesDr. Saurabh Saha M.D. (Age 48)Ph.D., CEO & Director Compensation: $1.04MDr. David M. Chao Ph.D. (Age 56)Chief Administrative Officer Compensation: $710.3kMr. John J. Crowley CPA (Age 50)CFO and Principal Financial & Accounting Officer Ms. Tia L. Bush (Age 53)Chief Technology & Quality Officer 1 recent tradesMs. Kristen K. Sheppard Esq.J.D., Senior Vice President of Investor Relations & Corporate CommunicationsMr. Iqbal J. Hussain L.L.B. (Age 43)General Counsel, Chief Compliance Officer & Corporate Secretary 1 recent tradesMs. Karen M. Anderson (Age 56)Chief People Officer 2 recent tradesDr. Gregory M. Weinhoff M.B.A. (Age 53)M.D., Chief Business Officer Compensation: $655kDr. Mario Alberto Accardi Ph.D.President of the Orexin ProgramMs. April DovholukSenior Vice President of Development Operations More Insider Trading Tools from MarketBeat Related Companies Intra-Cellular Therapies Insider Transactions Roivant Sciences Insider Transactions Revolution Medicines Insider Transactions Lantheus Insider Transactions Nuvalent Insider Transactions Elanco Animal Health Insider Transactions Cytokinetics Insider Transactions Blueprint Medicines Insider Transactions BridgeBio Pharma Insider Transactions TG Therapeutics Insider Transactions Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks That Wall Street Insiders Can’t Stop BuyingAppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to Avoid This page (NASDAQ:CNTA) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Elon Spotted at Weird Facility in Memphis? What Elon Musk is planning at a remote facility in Memphis may be his greatest achievement to date. Because...Paradigm Press | SponsoredLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberr...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
